Pontacyl Violet 6R

Pontacyl Violet 6R

SCHEMBL10080484

O=S(=O)(O)c1cc(O)c2c(O)c(/N=N/c3cccc4ccccc34)c(S(=O)(=O)O)cc2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 5/20 1.00
MAPK1 P28482 3/20 1.00
CYP2C9 P11712 2/20 1.00
DNASE1L3 Q13609 1/20 1.00
PRMT1 Q99873 2/20 0.71
HIF1A Q16665 3/20 0.69
ALDH1A1 P00352 2/20 0.69
TSHR P16473 1/20 0.65
PTPRA P18433 1/20 0.65
PTPRB P23467 1/20 0.65
CYP2C19 P33261 1/20 0.65
RAPGEF4 Q8WZA2 1/20 0.65
HSD17B10 Q99714 1/20 0.65
KMT2A Q03164 4/20 0.54
MEN1 O00255 3/20 0.54
THRB P10828 2/20 0.54
TDP1 Q9NUW8 2/20 0.54
PTPN11 Q06124 1/20 0.54
PHLPP2 Q6ZVD8 2/20 0.52
HTT P42858 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pontacyl Violet 6R SCHEMBL12282563 1.00 CYP1A2 (1.00) CYP1A2MAPK1CYP2C9DNASE1L3PRMT1
Pontacyl Violet 6R SCHEMBL29412925 1.00 CYP1A2 (1.00) CYP1A2MAPK1CYP2C9DNASE1L3PRMT1
SCHEMBL60352 0.89 CYP1A2 (0.80) CYP1A2MAPK1CYP2C9DNASE1L3PRMT1
SCHEMBL60351 0.89 CYP1A2 (0.80) CYP1A2MAPK1CYP2C9DNASE1L3PRMT1
SCHEMBL29767885 0.89 CYP1A2 (0.80) CYP1A2MAPK1CYP2C9DNASE1L3PRMT1
SCHEMBL11227186 0.89 CYP1A2 (0.80) CYP1A2MAPK1CYP2C9DNASE1L3PRMT1
SCHEMBL11227192 0.89 CYP1A2 (0.80) CYP1A2MAPK1CYP2C9DNASE1L3PRMT1
SCHEMBL15181277 0.89 CYP1A2 (0.79) CYP1A2MAPK1CYP2C9DNASE1L3PRMT1
SCHEMBL11763985 0.87 CYP1A2 (0.79) CYP1A2MAPK1CYP2C9DNASE1L3PRMT1
SCHEMBL70833 0.86 CYP1A2 (0.76) CYP1A2MAPK1CYP2C9DNASE1L3PRMT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012019106-A2 POSITIVE AND NEGATIVE MODULATORS OF NMDA RECEPTORS BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) 2012-02-09 WO disclosed
US-20090118135-A1 METHODS AND COMPOUNDS FOR REGULATING APOPTOSIS THE BURNHAM INSTITUTE (US) 2009-05-07 US disclosed
US-20090118135-A1 METHODS AND COMPOUNDS FOR REGULATING APOPTOSIS THE BURNHAM INSTITUTE (US) 2009-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118135-A1 METHODS AND COMPOUNDS FOR REGULATING APOPTOSIS BCL2, BAX, BAD CYP1A2 4401/4885MAPK1 2957/4885CYP2C9 4838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.